| scholarly article | Q13442814 |
| P50 | author | Carey K Anders | Q89228346 |
| Allison M Deal | Q90710081 | ||
| Olga Karginova | Q114340363 | ||
| David B Darr | Q114340364 | ||
| Charlene M Santos | Q114340366 | ||
| Ryan E Bash | Q114340367 | ||
| Maria J Sambade | Q114340372 | ||
| Nana Nikolaishvili-Feinberg | Q114340373 | ||
| Sara K O'Neal | Q41666834 | ||
| Yueh Lee | Q42516321 | ||
| C. Ryan Miller | Q57415228 | ||
| Marni B Siegel | Q64275606 | ||
| Amanda Van Swearingen | Q83462625 | ||
| P2093 | author name string | Joel S Parker | |
| Barbara Adamo | |||
| William Zamboni | |||
| Katie Sandison | |||
| Soha Bazyar | |||
| P2860 | cites work | Sites of distant recurrence and clinical outcomes in patients with metastatic triple-negative breast cancer: high incidence of central nervous system metastases | Q33715354 |
| Transcriptomic classification of genetically engineered mouse models of breast cancer identifies human subtype counterparts | Q33742688 | ||
| Biology, metastatic patterns, and treatment of patients with triple-negative breast cancer | Q34058510 | ||
| Deconstructing the molecular portraits of breast cancer | Q34154147 | ||
| Genomic analysis identifies unique signatures predictive of brain, lung, and liver relapse. | Q34192343 | ||
| Trapping of PARP1 and PARP2 by Clinical PARP Inhibitors | Q34309488 | ||
| αB-crystallin: a novel regulator of breast cancer metastasis to the brain | Q34378205 | ||
| Heterogeneous Blood–Tumor Barrier Permeability Determines Drug Efficacy in Experimental Brain Metastases of Breast Cancer | Q34393640 | ||
| Analysis of tumour- and stroma-supplied proteolytic networks reveals a brain-metastasis-promoting role for cathepsin S | Q34599128 | ||
| Incidence and outcome of BRCA mutations in unselected patients with triple receptor-negative breast cancer | Q34625335 | ||
| Pharmacokinetics and efficacy of PEGylated liposomal doxorubicin in an intracranial model of breast cancer. | Q34708283 | ||
| Cross-species hybridization of microarrays for studying tumor transcriptome of brain metastasis | Q35409064 | ||
| Treatment of Breast Cancer Brain Metastases | Q36057858 | ||
| Molecular characterization of basal-like and non-basal-like triple-negative breast cancer | Q36630430 | ||
| Results of a phase II open-label, non-randomized trial of cisplatin chemotherapy in patients with BRCA1-positive metastatic breast cancer | Q36924418 | ||
| Combined PI3K/mTOR and MEK inhibition provides broad antitumor activity in faithful murine cancer models | Q37024819 | ||
| Predicting drug responsiveness in human cancers using genetically engineered mice. | Q37187379 | ||
| gammaH2AX: a sensitive molecular marker of DNA damage and repair | Q37687078 | ||
| Poly(ADP-ribose) polymerase (PARP) inhibitors: Exploiting a synthetic lethal strategy in the clinic | Q37826009 | ||
| The DNA damage response and cancer therapy | Q37977004 | ||
| New targets for triple-negative breast cancer | Q38166755 | ||
| ABT-888, an orally active poly(ADP-ribose) polymerase inhibitor that potentiates DNA-damaging agents in preclinical tumor models | Q40138516 | ||
| High reproducibility using sodium hydroxide-stripped long oligonucleotide DNA microarrays. | Q40464248 | ||
| The triple negative paradox: primary tumor chemosensitivity of breast cancer subtypes | Q42511189 | ||
| Olaparib in patients with recurrent high-grade serous or poorly differentiated ovarian carcinoma or triple-negative breast cancer: a phase 2, multicentre, open-label, non-randomised study | Q44846367 | ||
| Activation and cleavage of caspase-3 in apoptosis induced by experimental cerebral ischemia. | Q48455875 | ||
| Significance analysis of microarrays applied to the ionizing radiation response | Q24606608 | ||
| Entrez Gene: gene-centered information at NCBI | Q24610128 | ||
| Genes that mediate breast cancer metastasis to the brain | Q24644008 | ||
| Effects of different tissue microenvironments on gene expression in breast cancer cells | Q27321107 | ||
| Systematic and integrative analysis of large gene lists using DAVID bioinformatics resources | Q27860739 | ||
| Specific killing of BRCA2-deficient tumours with inhibitors of poly(ADP-ribose) polymerase | Q28131711 | ||
| Bioinformatics enrichment tools: paths toward the comprehensive functional analysis of large gene lists | Q28131785 | ||
| Java Treeview--extensible visualization of microarray data | Q29547226 | ||
| Open source clustering software | Q29547702 | ||
| Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and advanced breast cancer: a proof-of-concept trial | Q30080035 | ||
| Titanium dioxide nanoparticles activate the ATM-Chk2 DNA damage response in human dermal fibroblasts | Q30432008 | ||
| MERTK receptor tyrosine kinase is a therapeutic target in melanoma. | Q30539324 | ||
| Human breast cancer metastases to the brain display GABAergic properties in the neural niche | Q30569512 | ||
| The molecular portraits of breast tumors are conserved across microarray platforms | Q33241398 | ||
| EGFR associated expression profiles vary with breast tumor subtype | Q33292502 | ||
| Breast cancer brain metastases: differences in survival depending on biological subtype, RPA RTOG prognostic class and systemic treatment after whole-brain radiotherapy (WBRT). | Q33511405 | ||
| The apoptosis cascade--morphological and immunohistochemical methods for its visualization | Q33680390 | ||
| P433 | issue | 4 | |
| P921 | main subject | murine model | Q122890741 |
| carboplatin | Q415588 | ||
| P304 | page(s) | 920-930 | |
| P577 | publication date | 2015-04-01 | |
| P1433 | published in | Molecular Cancer Therapeutics | Q2363144 |
| P1476 | title | Efficacy of Carboplatin Alone and in Combination with ABT888 in Intracranial Murine Models of BRCA-Mutated and BRCA-Wild-Type Triple-Negative Breast Cancer | |
| P478 | volume | 14 |
| Q38706298 | A diagnostic microdosing approach to investigate platinum sensitivity in non-small cell lung cancer. |
| Q36287407 | A novel intraperitoneal metastatic xenograft mouse model for survival outcome assessment of esophageal adenocarcinoma |
| Q57813899 | Breast cancer brain metastases show increased levels of genomic aberration-based homologous recombination deficiency scores relative to their corresponding primary tumors |
| Q51012619 | Combined kinase inhibitors of MEK1/2 and either PI3K or PDGFR are efficacious in intracranial triple-negative breast cancer. |
| Q92917085 | Current State of Platinum Complexes for the Treatment of Advanced and Drug-Resistant Breast Cancers |
| Q26739366 | Cytotoxic and targeted therapy for hereditary cancers |
| Q51604630 | Development and evaluation of a novel product to remove surface contamination of hazardous drugs. |
| Q97542735 | Efficacy and pharmacodynamics of niraparib in BRCA-mutant and wild-type intracranial triple-negative breast cancer murine models |
| Q41280444 | Efficacy and pharmacokinetics of a modified acid-labile docetaxel-PRINT(®) nanoparticle formulation against non-small-cell lung cancer brain metastases |
| Q33440543 | Efficacy of the PARP Inhibitor Veliparib with Carboplatin or as a Single Agent in Patients with Germline BRCA1- or BRCA2-Associated Metastatic Breast Cancer: California Cancer Consortium Trial NCT01149083. |
| Q38829087 | Immunotherapy and targeted therapy in brain metastases: emerging options in precision medicine. |
| Q37630473 | PARP inhibitor increases chemosensitivity by upregulating miR-664b-5p in BRCA1-mutated triple-negative breast cancer |
| Q38795712 | PARP inhibitors as antitumor agents: a patent update (2013-2015). |
| Q90458957 | Patterns of recurrence and metastasis in BRCA1/BRCA2-associated breast cancers |
| Q91793950 | Response to Olaparib in a Patient with Germline BRCA2 Mutation and Breast Cancer Leptomeningeal Carcinomatosis |
| Q50271137 | Revisiting the definition of estrogen receptor positivity in HER2-negative primary breast cancer. |
| Q52688051 | Superior Therapeutic Efficacy of Nanoparticle Albumin Bound Paclitaxel Over Cremophor-Bound Paclitaxel in Experimental Esophageal Adenocarcinoma. |
| Q55457376 | Synthetic Lethality of PARP Inhibition and Ionizing Radiation is p53-dependent. |
| Q52721270 | Targeting Tissue Factor for Immunotherapy of Triple-Negative Breast Cancer Using a Second-Generation ICON. |
| Q55287222 | Understanding patterns of brain metastasis in breast cancer and designing rational therapeutic strategies. |
| Q89021957 | nab-Paclitaxel plus carboplatin or gemcitabine versus gemcitabine plus carboplatin as first-line treatment of patients with triple-negative metastatic breast cancer: results from the tnAcity trial |
Search more.